Weight rebound occurs after stopping the medication because your natural hunger hormones return to baseline levels, not because the medication changes your metabolism in a harmful way
The role of SCFAs in diseases remains controversial, and the underlying mechanisms involved are still unclear
however, production of glutathione may not always be enough to optimize its potential
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-l randomized trial
Rapid improvements in blood sugar may potentially be associated with a temporary worsening of diabetic retinopathy
If Phase 3 trials fail to replicate the Phase 2 results, or if unexpected safety issues emerge, the FDA could delay or deny approval